Bayer Aktienges Ads (BAYRY) 100.5100 $BAYRY
Medical Device Consolidation Frenzy: Here's How to Play it
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:00AM CDT
The medical device majors struggling with their core businesses are often on the lookout for emerging therapies through acquisitions and alliances.
ABT: 41.89 (+0.53), JNJ: 122.85 (+0.34), ZBH: 124.89 (+2.87), LDRH: 36.97 (-0.01), MDT: 88.36 (+0.87), TMO: 152.69 (+3.63), STJ: 80.58 (+0.43), HTWR: 57.64 (+0.11), XRAY: 63.39 (+0.89), NUVA: 60.82 (+1.11), FEIC: 106.78 (-0.23)
Former Bayer and Pharmacia Senior Executive Rolf A. Classon Joins the Sequana Medical AG Board as Chairman
PR Newswire - Fri Jul 01, 1:00AM CDT
Sequana Medical AG, a privately held medical device company focused on the development and commercialization of innovative, implantable pump systems to manage fluid build-up in patients with liver disease, congestive heart failure and certain cancers, announced today that Rolf A. Classon, former top executive of Bayer AG and Pharmacia AB, has been appointed Chairman of the Board of Directors.
These Large Pharmaceutical Stocks Should be on your Radar
Zacks Premium Research - Zacks Investment Research - Wed Jun 29, 5:33PM CDT
The industry has been building momentum, so this might be a nice time to jump into the space.
PFE: 36.12 (+0.35), BMY: 75.28 (+1.20)
Pfizer Investing $350M in China, Setting up Biotech Center
Arpita Dutt - Zacks Investment Research - Tue Jun 28, 9:38AM CDT
This will be Pfizer's (PFE) third biotechnology center globally and the first in Asia.
JNJ: 122.85 (+0.34), PFE: 36.12 (+0.35), BMY: 75.28 (+1.20)
CRISPR Therapeutics Raises Additional $38M as Part of Series B Financing
BusinessWire - Fri Jun 24, 6:00AM CDT
CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines, today announced an additional $38 million closing of its Series B financing. This additional investment brings the total Series B financing round to nearly $140 million. The previous Series B investment was led by Vertex Pharmaceuticals and Bayer Global Investments, an affiliate of Bayer AG, as part of the company's strategic investment in CRISPR Therapeutics. This second, oversubscribed closing of the Series B financing, includes several new institutional investors and specialized healthcare funds. Participating investors in this round include Franklin Templeton Investments, New Leaf Venture Partners, funds advised by Clough Capital Partners L.P. and Wellington Capital Management L.L.P., and other undisclosed funds specializing in life sciences.
Paratek Reports Positive Phase III Data on Antibiotic Drug
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:03AM CDT
Paratek Pharmaceuticals (PRTK) announced positive phase III results on omadacycline for the treatment of acute bacterial skin and skin structure infections.
AGN: 240.59 (+2.58), PFE: 36.12 (+0.35), PRTK: 13.29 (-0.12)
Philip Blake of Bayer Recognized in STEMconnector's® 100 CEO Leaders in STEM
PR Newswire - Thu Jun 16, 11:49AM CDT
Philip Blake, President of Bayer Corporation and Head of the Americas Region for Pharmaceuticals, has been recognized in STEMconnector's® 100 CEO Leaders in STEM publication.
Stock Market News for June 01, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:10AM CDT
Benchmarks ended mostly in the red on Tuesday following a cautious stance among investors ahead of the release of major economic reports this week
KO: 45.38 (+0.29), MON: 102.68 (+2.04), EA: 78.26 (+1.64), PFE: 36.12 (+0.35), SYY: 51.59 (+0.40), STZ: 165.99 (-0.02), XOM: 93.54 (+0.58), PEP: 108.27 (+0.78), NVDA: 50.85 (+1.96), DD: 63.69 (+1.77), PG: 85.77 (+0.94), CVX: 104.77 (+1.72), DOW: 49.40 (+1.20), PPG: 106.32 (+3.29), ECL: 119.20 (+1.61)
Stock Market News for May 31, 2016
Zacks Equity Research - Zacks Investment Research - Tue May 31, 9:10AM CDT
Benchmarks finished in the green on Friday after Fed Chairwoman Janet Yellen said a rate rise might be appropriate in coming months
DLTR: 95.08 (+0.45), GS: 150.38 (+3.38), MON: 102.68 (+2.04), JPM: 61.83 (+1.25), C: 41.98 (+0.69), WFC: 47.79 (+0.99), BAC: 13.17 (+0.16), ULTA: 250.82 (+3.53), TOL: 28.24 (+1.01), BHI: 43.69 (+0.15)
Monsanto rejects $62B Bayer bid, but still open to talks
AP - Tue May 24, 5:10PM CDT
NEW YORK (AP) — Monsanto rejected Bayer's $62 billion takeover bid, calling it "incomplete and financially inadequate."
MON: 102.68 (+2.04)
ETFs to Watch on Monsanto Buyout Offer
Sweta Killa - Zacks Investment Research - Tue May 24, 8:46AM CDT
The German chemical giant made all-cash bid to acquire Monsanto for $62 billion, including debt, putting these ETFs on spotlight.
XLB: 46.96 (+1.14), SYT: 75.09 (-0.10), MON: 102.68 (+2.04), MOO: 47.89 (+0.78), VEGI: 22.98 (+0.36), IYM: 77.14 (+2.03), DD: 63.69 (+1.77), DOW: 49.40 (+1.20)
How would Bayer-Monsanto affect workers, farmers, investors?
By DAVID McHUGH - AP - Mon May 23, 4:32PM CDT
FRANKFURT, Germany (AP) — Bayer wants to buy Monsanto for $62 billion, hooking up the German chemical and drug company with the St. Louis-based producer of seeds and weed-killers.
MON: 102.68 (+2.04)
Business Highlights
By The Associated Press - AP - Mon May 23, 4:30PM CDT
___
VIA: 49.93 (+2.16), MON: 102.68 (+2.04), PFE: 36.12 (+0.35), BAC: 13.17 (+0.16), CBS.A: 60.39 (+1.59), BA: 130.09 (+2.92), VIAB: 45.20 (+2.16), CBS: 57.08 (+0.97)
Bayer and Monsanto could combine plant, pet, people products
By LINDA A. JOHNSON and MATTHEW PERRONE - AP - Mon May 23, 4:05PM CDT
A merger between Bayer and Monsanto would put together two giant chemical makers, one focused on plants and another that also makes products for people and animals. Here's a look at their products, which have more than $65 billion in total annual revenue.
MON: 102.68 (+2.04)
Viacom (VIA) Redstone Drama Rivals Original Programming
Mark Vickery - Zacks Investment Research - Mon May 23, 9:36AM CDT
A power play is ongoing at the board of National Amusements, majority shareholders at Viacom and CBS.
VIA: 49.93 (+2.16), MON: 102.68 (+2.04), CBS: 57.08 (+0.97)
Bayer to Buy Monsanto for $62B to Boost Agriculture Portfolio
Zacks Equity Research - Zacks Investment Research - Mon May 23, 8:30AM CDT
Bayer (BAYRY) to acquire all issued and outstanding shares of common stock of Monsanto (MON) at $122 per share in an aggregate all-cash offer worth $62 billion.
MON: 102.68 (+2.04), PFE: 36.12 (+0.35), BMY: 75.28 (+1.20)
Medical Device Consolidation Frenzy: Here's How to Play it
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:00AM CDT
The medical device majors struggling with their core businesses are often on the lookout for emerging therapies through acquisitions and alliances.
ABT: 41.89 (+0.53), JNJ: 122.85 (+0.34), ZBH: 124.89 (+2.87), LDRH: 36.97 (-0.01), MDT: 88.36 (+0.87), TMO: 152.69 (+3.63), STJ: 80.58 (+0.43), HTWR: 57.64 (+0.11), XRAY: 63.39 (+0.89), NUVA: 60.82 (+1.11), FEIC: 106.78 (-0.23)
Former Bayer and Pharmacia Senior Executive Rolf A. Classon Joins the Sequana Medical AG Board as Chairman
PR Newswire - Fri Jul 01, 1:00AM CDT
Sequana Medical AG, a privately held medical device company focused on the development and commercialization of innovative, implantable pump systems to manage fluid build-up in patients with liver disease, congestive heart failure and certain cancers, announced today that Rolf A. Classon, former top executive of Bayer AG and Pharmacia AB, has been appointed Chairman of the Board of Directors.
These Large Pharmaceutical Stocks Should be on your Radar
Zacks Premium Research - Zacks Investment Research - Wed Jun 29, 5:33PM CDT
The industry has been building momentum, so this might be a nice time to jump into the space.
PFE: 36.12 (+0.35), BMY: 75.28 (+1.20)
Pfizer Investing $350M in China, Setting up Biotech Center
Arpita Dutt - Zacks Investment Research - Tue Jun 28, 9:38AM CDT
This will be Pfizer's (PFE) third biotechnology center globally and the first in Asia.
JNJ: 122.85 (+0.34), PFE: 36.12 (+0.35), BMY: 75.28 (+1.20)
CRISPR Therapeutics Raises Additional $38M as Part of Series B Financing
BusinessWire - Fri Jun 24, 6:00AM CDT
CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines, today announced an additional $38 million closing of its Series B financing. This additional investment brings the total Series B financing round to nearly $140 million. The previous Series B investment was led by Vertex Pharmaceuticals and Bayer Global Investments, an affiliate of Bayer AG, as part of the company's strategic investment in CRISPR Therapeutics. This second, oversubscribed closing of the Series B financing, includes several new institutional investors and specialized healthcare funds. Participating investors in this round include Franklin Templeton Investments, New Leaf Venture Partners, funds advised by Clough Capital Partners L.P. and Wellington Capital Management L.L.P., and other undisclosed funds specializing in life sciences.
Paratek Reports Positive Phase III Data on Antibiotic Drug
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:03AM CDT
Paratek Pharmaceuticals (PRTK) announced positive phase III results on omadacycline for the treatment of acute bacterial skin and skin structure infections.
AGN: 240.59 (+2.58), PFE: 36.12 (+0.35), PRTK: 13.29 (-0.12)
Philip Blake of Bayer Recognized in STEMconnector's® 100 CEO Leaders in STEM
PR Newswire - Thu Jun 16, 11:49AM CDT
Philip Blake, President of Bayer Corporation and Head of the Americas Region for Pharmaceuticals, has been recognized in STEMconnector's® 100 CEO Leaders in STEM publication.
Stock Market News for June 01, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:10AM CDT
Benchmarks ended mostly in the red on Tuesday following a cautious stance among investors ahead of the release of major economic reports this week
KO: 45.38 (+0.29), MON: 102.68 (+2.04), EA: 78.26 (+1.64), PFE: 36.12 (+0.35), SYY: 51.59 (+0.40), STZ: 165.99 (-0.02), XOM: 93.54 (+0.58), PEP: 108.27 (+0.78), NVDA: 50.85 (+1.96), DD: 63.69 (+1.77), PG: 85.77 (+0.94), CVX: 104.77 (+1.72), DOW: 49.40 (+1.20), PPG: 106.32 (+3.29), ECL: 119.20 (+1.61)
Stock Market News for May 31, 2016
Zacks Equity Research - Zacks Investment Research - Tue May 31, 9:10AM CDT
Benchmarks finished in the green on Friday after Fed Chairwoman Janet Yellen said a rate rise might be appropriate in coming months
DLTR: 95.08 (+0.45), GS: 150.38 (+3.38), MON: 102.68 (+2.04), JPM: 61.83 (+1.25), C: 41.98 (+0.69), WFC: 47.79 (+0.99), BAC: 13.17 (+0.16), ULTA: 250.82 (+3.53), TOL: 28.24 (+1.01), BHI: 43.69 (+0.15)
Monsanto rejects $62B Bayer bid, but still open to talks
AP - Tue May 24, 5:10PM CDT
NEW YORK (AP) — Monsanto rejected Bayer's $62 billion takeover bid, calling it "incomplete and financially inadequate."
MON: 102.68 (+2.04)
ETFs to Watch on Monsanto Buyout Offer
Sweta Killa - Zacks Investment Research - Tue May 24, 8:46AM CDT
The German chemical giant made all-cash bid to acquire Monsanto for $62 billion, including debt, putting these ETFs on spotlight.
XLB: 46.96 (+1.14), SYT: 75.09 (-0.10), MON: 102.68 (+2.04), MOO: 47.89 (+0.78), VEGI: 22.98 (+0.36), IYM: 77.14 (+2.03), DD: 63.69 (+1.77), DOW: 49.40 (+1.20)
How would Bayer-Monsanto affect workers, farmers, investors?
By DAVID McHUGH - AP - Mon May 23, 4:32PM CDT
FRANKFURT, Germany (AP) — Bayer wants to buy Monsanto for $62 billion, hooking up the German chemical and drug company with the St. Louis-based producer of seeds and weed-killers.
MON: 102.68 (+2.04)
Business Highlights
By The Associated Press - AP - Mon May 23, 4:30PM CDT
___
VIA: 49.93 (+2.16), MON: 102.68 (+2.04), PFE: 36.12 (+0.35), BAC: 13.17 (+0.16), CBS.A: 60.39 (+1.59), BA: 130.09 (+2.92), VIAB: 45.20 (+2.16), CBS: 57.08 (+0.97)
Bayer and Monsanto could combine plant, pet, people products
By LINDA A. JOHNSON and MATTHEW PERRONE - AP - Mon May 23, 4:05PM CDT
A merger between Bayer and Monsanto would put together two giant chemical makers, one focused on plants and another that also makes products for people and animals. Here's a look at their products, which have more than $65 billion in total annual revenue.
MON: 102.68 (+2.04)
Viacom (VIA) Redstone Drama Rivals Original Programming
Mark Vickery - Zacks Investment Research - Mon May 23, 9:36AM CDT
A power play is ongoing at the board of National Amusements, majority shareholders at Viacom and CBS.
VIA: 49.93 (+2.16), MON: 102.68 (+2.04), CBS: 57.08 (+0.97)
Bayer to Buy Monsanto for $62B to Boost Agriculture Portfolio
Zacks Equity Research - Zacks Investment Research - Mon May 23, 8:30AM CDT
Bayer (BAYRY) to acquire all issued and outstanding shares of common stock of Monsanto (MON) at $122 per share in an aggregate all-cash offer worth $62 billion.
MON: 102.68 (+2.04), PFE: 36.12 (+0.35), BMY: 75.28 (+1.20)
